IOP-lowering effect lasting for 24 hours of Tapcom combination ophthalmic solution switched from Tapros ophthalmic solution 0.0015% and Timoptol XE ophthalmic solution 0.5%.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Mar 2017
At a glance
- Drugs Tafluprost/timolol (Primary) ; Tafluprost; Timolol
- Indications Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Santen Pharmaceutical
- 06 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 20 Sep 2016 New trial record